Hannah [Unknown]'s questions to BioLife Solutions Inc (BLFS) leadership • Q3 2024
Question
An analyst from an unknown firm asked for details on the pro forma gross margins, OpEx savings, and depreciation following the SciSafe divestiture. They also inquired about the long-term growth outlook for 2025, considering recent revenue swings from customer destocking.
Answer
Executive Troy Wichterman directed the analyst to the company's 8-K filing, which shows a pro forma adjusted gross margin of 60% for the first half of 2024 without SciSafe, noting a minimal expected impact on future adjusted EBITDA. CEO Roderick de Greef deferred specific 2025 guidance to January but highlighted four consecutive quarters of sequential growth and stated that the destocking issue is now resolved.